The New England journal of medicine, 2021-12, Vol.385 (23), p.e81
- Weinreich, David M
- Sivapalasingam, Sumathi
- Norton, Thomas
- Ali, Shazia
- Gao, Haitao
- Bhore, Rafia
- Xiao, Jing
- Hooper, Andrea T
- Hamilton, Jennifer D
- Musser, Bret J
- Rofail, Diana
- Hussein, Mohamed
- Im, Joseph
- Atmodjo, Dominique Y
- Perry, Christina
- Pan, Cynthia
- Mahmood, Adnan
- Hosain, Romana
- Davis, John D
- Turner, Kenneth C
- Baum, Alina
- Kyratsous, Christos A
- Kim, Yunji
- Cook, Amanda
- Kampman, Wendy
- Roque-Guerrero, Lilia
- Acloque, Gerard
- Aazami, Hessam
- Cannon, Kevin
- Simón-Campos, J. Abraham
- Bocchini, Joseph A
- Kowal, Bari
- DiCioccio, A. Thomas
- Soo, Yuhwen
- Geba, Gregory P
- Stahl, Neil
- Lipsich, Leah
- Braunstein, Ned
- Herman, Gary
- Yancopoulos, George D
2021
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Weinreich, David M
- Sivapalasingam, Sumathi
- Norton, Thomas
- Ali, Shazia
- Gao, Haitao
- Bhore, Rafia
- Xiao, Jing
- Hooper, Andrea T
- Hamilton, Jennifer D
- Musser, Bret J
- Rofail, Diana
- Hussein, Mohamed
- Im, Joseph
- Atmodjo, Dominique Y
- Perry, Christina
- Pan, Cynthia
- Mahmood, Adnan
- Hosain, Romana
- Davis, John D
- Turner, Kenneth C
- Baum, Alina
- Kyratsous, Christos A
- Kim, Yunji
- Cook, Amanda
- Kampman, Wendy
- Roque-Guerrero, Lilia
- Acloque, Gerard
- Aazami, Hessam
- Cannon, Kevin
- Simón-Campos, J. Abraham
- Bocchini, Joseph A
- Kowal, Bari
- DiCioccio, A. Thomas
- Soo, Yuhwen
- Geba, Gregory P
- Stahl, Neil
- Lipsich, Leah
- Braunstein, Ned
- Herman, Gary
- Yancopoulos, George D
- Titel
- REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
- Ist Teil von
- The New England journal of medicine, 2021-12, Vol.385 (23), p.e81
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2021
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- This phase 3, placebo-controlled platform trial evaluated a single infusion of casirivimab and imdevimab (REGEN-COV) at 2400-mg and 1200-mg doses in outpatients with acute SARS-CoV-2 infection. The incidence of Covid-19–related hospitalization was lower and recovery was faster among patients who received the antibody combination than among those who received placebo.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2108163Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8522800
- Format
- –
- Schlagworte
- Adolescent, Adult, Adverse events, Antibodies, Antibodies, Monoclonal, Humanized - administration & dosage, Antibodies, Monoclonal, Humanized - pharmacokinetics, Antibodies, Monoclonal, Humanized - pharmacology, Antibodies, Neutralizing - administration & dosage, Antibodies, Neutralizing - pharmacology, Antiviral Agents - administration & dosage, Antiviral Agents - pharmacokinetics, Antiviral Agents - pharmacology, Confidence intervals, Coronavirus, Coronaviruses, COVID-19, COVID-19 - drug therapy, COVID-19 - mortality, Death, Dose-Response Relationship, Drug, Double-Blind Method, Drug Combinations, Female, Hospitalization, Hospitalization - statistics & numerical data, Humans, Infectious Disease, Intravenous administration, Kaplan-Meier Estimate, Laboratories, Male, Middle Aged, Monoclonal antibodies, Original, Patients, Placebos, Pregnancy, Pregnancy Complications, Infectious - drug therapy, Proportional Hazards Models, Risk factors, Severe acute respiratory syndrome coronavirus 2, Statistical analysis, Viral Load - drug effects, Young Adult